Get the Stockscreener App
9.64
0.63%
0.06
Pre-market:
9.67
0.03
+0.31%
Biohaven Ltd stock is traded at $9.64, with a volume of 1.65M.
It is up +0.63% in the last 24 hours and down -15.14% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$9.58
Open:
$9.73
24h Volume:
1.65M
Relative Volume:
0.60
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.385
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
-5.58%
1M Performance:
-15.14%
6M Performance:
-28.54%
1Y Performance:
-66.93%
1-Day Range:
$9.55
$9.9599
1-Week Range:
$9.5135
$11.20
52-Week Range:
$7.48
$31.18
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.64 | 1.45B | 0 | -738.82M | -610.15M | -6.9602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Ltd. ($BHVN) CEO 2025 Pay Revealed - Quiver Quantitative
Integral Health Asset Management LLC Buys 350,000 Shares of Biohaven Ltd. $BHVN - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Capital Research Global Investors Raises Position in Biohaven Ltd. $BHVN - MarketBeat
Macro Review: Is Biohaven Ltd gaining market shareWeekly Trading Summary & Technical Entry and Exit Tips - baoquankhu1.vn
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00 - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration - simplywall.st
Raymond James Maintains Strong Buy on Biohaven Ltd. (BHVN) March 2026 - Meyka
Biohaven (BHVN) director trust purchase corrected to 28,400 shares - Stock Titan
Raymond James reiterates Strong Buy on Biohaven stock after competitor data - Investing.com Australia
Raymond James reiterates Strong Buy on Biohaven stock after competitor data By Investing.com - Investing.com South Africa
Biohaven Reports Q4 EPS Beat Expectations, Plans Stock Issuance - Intellectia AI
Biohaven (NYSE:BHVN) Shares Gap UpTime to Buy? - MarketBeat
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets - Bez Kabli
What's Going On With Biohaven Stock On Monday? - Benzinga
Breakout Watch: Can Biohaven Ltd stock outperform in a bear marketJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Death Cross: Is Biohaven Ltd a stock for growth or value investors2025 Winners & Losers & Reliable Trade Execution Plans - baoquankhu1.vn
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN: HC Wainwright & Co. Lowers Price Target While Maintaining - GuruFocus
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com Nigeria
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Biohaven reduces scope of R&D cuts as pipeline progresses - Fierce Biotech
RBC Raises Price Target on Biohaven to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. Common Shares (NY: BHVN - The Chronicle-Journal
Biohaven Ltd reports results for the quarter ended September 30Earnings Summary - TradingView
Biohaven (NYSE:BHVN) Announces Earnings Results - MarketBeat
Biohaven (NYSE: BHVN) refocuses pipeline after key trial and FDA setbacks - Stock Titan
Biohaven 10-K: $0 Revenue, $(0.74)B Net Loss; Cash ~$319M - TradingView
Earnings Flash (BHVN) Biohaven Ltd. Posts Q4 Adjusted Loss $0.90 per Share, vs. FactSet Est of $-0.87 - marketscreener.com
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors - simplywall.st
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
BHVN Should I Buy - Intellectia AI
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):